'Future' Of AIDS Vaccine Research In Lab Research, Smaller Trials, Editorial Says
Main Category: HIV / AIDSAlso Included In: Immune System / Vaccines; Clinical Trials / Drug Trials
Article Date: 02 Apr 2008 - 12:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
The recent "failure" of a Merck HIV/AIDS vaccine has "led to two conflicting calls for action, neither of which got it right," a Los Angeles Times editorial says. Grant recipients "wanted the vaccine search to go on as before," while "treatment activists wanted the money stripped from research," the editorial says, adding that NIH at a conference last week "appeared to be taking a wiser approach" and said that it "would continue funding vaccine research" with a likely focus on "basic research and smaller, less expensive trials."
After the Merck trial was halted, some groups "lost little time ... in calling for vaccine funding to be rerouted to treatment and prevention," according to the editorial. It adds that U.S. funding for HIV/AIDS vaccine research is less than $700 million annually -- a "relative pittance compared with that for treatment and prevention, which stands at more than $15 billion annually and is expected to at least double in the next year." It is "too easy to forget that people can develop resistance to" antiretroviral drugs and "suffer significant side effects," the editorial says, adding that the "research effort that brought about these treatments was a tremendous achievement, but scientists still have much to learn about the virus."
"It made sense to start the vaccine efforts with big clinical trials that, if successful, would have led quickly to drug licensing" because the "need for a vaccine was urgent," the editorial says, adding, "Now, however, we know that these trials cost too much and take too long." NIH officials are "right to say that the best future for an AIDS vaccine lies in the laboratory and in narrower trials that can point to the most promising paths while they add to our knowledge of the disease," the editorial concludes (Los Angeles Times, 4/1).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our hiv / aids section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/102486.php>
APA
http://www.medicalnewstoday.com/releases/102486.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



